Katherine Vega Stultz is a seasoned biotech executive with over two decades of experience in advancing therapeutics across various modalities and diseases. She currently serves as the Chief Executive Officer and Board Director at BrainXell, a biotechnology company specializing in central nervous system (CNS) disease models and regenerative cell therapies. At BrainXell, Katherine leads the company's efforts to expand its research tools and therapeutic platforms, focusing on conditions such as Parkinson's disease and ALS.

Prior to her role at BrainXell, Katherine was the President and CEO of Ocelot Bio, a clinical-stage company focused on developing innovative therapeutics to significantly improve outcomes for patients with end-stage liver disease. She has also held leadership positions at Graphite Bio and Celgene, where she advanced clinical development programs and led global project and portfolio management in hematology/oncology.

Katherine holds a Bachelor of Science in Mechanical Engineering with a concentration in Biomedical Applications from Cornell University. Throughout her career, she has been a strong advocate for diversity and inclusion, actively promoting gender parity and creating opportunities for others in the biotech industry. Her leadership is characterized by a commitment to innovation, team empowerment, and delivering impactful solutions for patients.